Related Experiment Video
Updated: May 11, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
[Melanoma- finally good news]
Andreas Wicki1, Andreas W Arnold, Peter H Itin
1Departement Biomedizin, Universitätsspital und Universität Basel. awicki@uhbs.ch
Praxis
|May 23, 2013
Summary
Two novel systemic therapies, ipilimumab and vemurafenib, now offer improved survival for malignant melanoma patients. These treatments represent significant advancements in metastatic melanoma care.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Malignant melanoma lacked effective systemic therapies prolonging overall survival until recently.
- Significant advancements in treatment options have emerged in the past two years.
Purpose of the Study:
- To highlight the impact of two new therapeutic approaches on the prognosis of malignant melanoma.
- To introduce ipilimumab and vemurafenib as treatments with proven survival benefits.
Main Methods:
- Review of recent advancements in systemic therapy for malignant melanoma.
- Description of ipilimumab as a cytotoxic T-cell activator.
- Description of vemurafenib as a specific BRAF inhibitor.
Main Results:
- Ipilimumab induces immune responses, leading to prolonged remission in 15-20% of patients.
- Vemurafenib induces rapid and complete remissions in patients with BRAF V600E mutated melanomas.
- Both ipilimumab and vemurafenib have demonstrated a proven survival benefit in metastatic melanoma.
Conclusions:
- Two new systemic therapies, ipilimumab and vemurafenib, have significantly improved the prognosis for malignant melanoma.
- These treatments offer new hope and improved survival outcomes for patients with metastatic melanoma.
Related Concept Videos
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...